Fusion Antibodies plc, incorporated in November 2000, is a public limited company registered in Northern Ireland with its base at Springbank Road, Belfast. Its primary listed activities are research and experimental development on biotechnology, alongside other professional, scientific and technical services. Within the biotech sector, the company is known for its work in antibody engineering, typically providing services such as antibody humanisation, affinity maturation, expression, and developability assessment to therapeutic and diagnostic developers. These services are contract research offerings, meaning Fusion Antibodies works with clients to optimise antibody candidates for downstream development. As a plc with a focused specialism, the firm likely operates as a mid-sized enterprise, with teams in molecular biology, protein science, and cell biology. Its location in Belfast places it within the UK's growing life sciences cluster, and it may also serve an international client base, though specific geographic reach is not stated. The company holds a Skilled Worker sponsor licence with an A rating from UK Visas and Immigration, confirming its eligibility to recruit non-UK nationals under the points-based system. This is a clear signal that the business actively employs overseas talent, making it relevant to job seekers, particularly those with skills in biotechnology research, assay development, and regulatory affairs. The key focus of Fusion Antibodies is evidently the development and application of antibody technologies to support drug discovery and diagnostics. Its public listing suggests a level of financial maturity and accountability. For prospective applicants, the company's sector and sponsor status indicate sustained demand for qualified professionals. No additional information about the company's current vacancies or international operations is available from the provided data, but the sponsor licence alone suggests ongoing interest in hiring from overseas.

Fusion Antibodies plc, incorporated in November 2000, is a public limited company registered in Northern Ireland with its base at Springbank Road, Belfast. Its primary listed activities are research and experimental development on biotechnology, alongside other professional, scientific and technical services. Within the biotech sector, the company is known for its work in antibody engineering, typically providing services such as antibody humanisation, affinity maturation, expression, and developability assessment to therapeutic and diagnostic developers. These services are contract research offerings, meaning Fusion Antibodies works with clients to optimise antibody candidates for downstream development. As a plc with a focused specialism, the firm likely operates as a mid-sized enterprise, with teams in molecular biology, protein science, and cell biology. Its location in Belfast places it within the UK's growing life sciences cluster, and it may also serve an international client base, though specific geographic reach is not stated. The company holds a Skilled Worker sponsor licence with an A rating from UK Visas and Immigration, confirming its eligibility to recruit non-UK nationals under the points-based system. This is a clear signal that the business actively employs overseas talent, making it relevant to job seekers, particularly those with skills in biotechnology research, assay development, and regulatory affairs. The key focus of Fusion Antibodies is evidently the development and application of antibody technologies to support drug discovery and diagnostics. Its public listing suggests a level of financial maturity and accountability. For prospective applicants, the company's sector and sponsor status indicate sustained demand for qualified professionals. No additional information about the company's current vacancies or international operations is available from the provided data, but the sponsor licence alone suggests ongoing interest in hiring from overseas.